Alzinova (ALZ) Q1 2026 earnings summary

Executive summary

• Advanced ALZ-101 vaccine candidate toward Phase II, supported by positive Phase Ib results and FDA Fast Track designation.

• Strengthened financial position via a SEK 36.5 million rights issue, enabling continued development.

• Initiated collaborations with Dr. Marwan Sabbagh and Amsterdam UMC for clinical and diagnostic advancements.

• Expanded business model to include diagnostics, aiming for early Alzheimer's detection and new revenue streams.

Financial highlights

• Loss after financial items for Q1 2026 was SEK -6,024 thousand, compared to SEK -5,731 thousand in Q1 2025.

• Cash flow for the period was SEK 11,062 thousand, up from SEK -11,094 thousand year-over-year.

• Cash and cash equivalents at period end were SEK 11,381 thousand, up from SEK 3,592 thousand.

• Total expenses for Q1 2026 were SEK -9,883 thousand, with R&D costs of SEK -4,911 thousand.

• Equity at period end was SEK 148,711 thousand, equity ratio 93.8%.

Outlook and guidance

• Focus remains on advancing ALZ-101 to Phase II, progressing partnership discussions, and developing diagnostics.

• Diagnostics collaboration with Amsterdam UMC expected to yield initial results in Q3 2026.

• TO4 warrant program in Q2 could provide up to SEK 60 million in additional proceeds.